Manning J Sloan, Haykal Radwan F, Connor Pamela D, Cunningham Patricia D, Jackson W Clay, Long Stephanie
From Mood Clinic, Family Medicine Department, University of Tennessee, Memphis, TN, USA.
J Affect Disord. 2005 Feb;84(2-3):259-66. doi: 10.1016/j.jad.2004.01.016.
The treatment of bipolar depression remains problematic. Lamotrigine has been shown in randomized controlled studies to be efficacious in preventing bipolar depression and rapid cycling states.
Twenty-four women with cyclothymic temperament and refractory depression were recruited from four outpatient sites (three primary care and one psychiatric) and treated with lamotrigine in a naturalistic, open-label study. Temperament was determined by responses on the TEMP-A self-rating scale. Eighteen (75%) of these cyclothymic patients also scored high on the depressive temperament. Eighteen (75%) met DSM-IV criteria for bipolar II disorder. In two thirds of the cases, lamotrigine was add-on therapy to an antidepressant. Response to therapy was assessed using the DSM-IV Global Assessment of Functioning (GAF).
This study was naturalistic in design, without controls or blinds.
Of the 23 patients who remained in the study, 16 (70%) had significant, sustained responses. Of these 16, 12 (75% of responders, 52% of the total) had remissions (GAF > 80) sustained longer than 12 months. Robust, sustained responses to lamotrigine monotherapy were seen in 4 patients (17%). Seven patients (30%) received no apparent benefit from lamotrigine.
Lamotrigine induced prolonged illness remissions in a substantial number of female patients whose symptoms were both complex and refractory. Most manifested high scores on the cyclothymic and depressive temperaments, and prior refractoriness to multiple antidepressant and antidepressant/mood stabilizer combinations, before remitting with lamotrigine augmentation or monotherapy.
双相抑郁的治疗仍然存在问题。在随机对照研究中,拉莫三嗪已被证明在预防双相抑郁和快速循环状态方面有效。
从四个门诊地点(三个初级保健机构和一个精神科机构)招募了24名具有环性心境气质且难治性抑郁的女性,并在一项自然主义、开放标签研究中用拉莫三嗪进行治疗。气质通过TEMP - A自评量表的回答来确定。这些环性心境障碍患者中有18名(75%)在抑郁气质方面得分也很高。18名(75%)符合DSM - IV双相II型障碍标准。在三分之二的病例中,拉莫三嗪是添加到抗抑郁药上的治疗方法。使用DSM - IV功能总体评定量表(GAF)评估治疗反应。
本研究在设计上是自然主义的,没有对照组或盲法。
在23名留在研究中的患者中,16名(70%)有显著的、持续的反应。在这16名患者中,12名(反应者中的75%,占总数的52%)病情缓解(GAF > 80)且持续时间超过12个月。4名患者(17%)对拉莫三嗪单药治疗有强烈、持续的反应。7名患者(30%)未从拉莫三嗪中获得明显益处。
拉莫三嗪使大量症状复杂且难治的女性患者病情得到长期缓解。大多数患者在环性心境和抑郁气质方面得分较高,并且在使用拉莫三嗪增效或单药治疗缓解之前,对多种抗抑郁药以及抗抑郁药/心境稳定剂联合治疗均有耐药性。